Cachexia News and Research

RSS

Cachexia is a condition which denotes the excessive loss of weight. It occurs because of the depletion of adipose tissue and muscle mass in people who are not trying to lose weight.

Mitofusin 2 protein could serve as therapeutic target to ameliorate sarcopenia in older adults

One of the alterations that most affects the quality of life of the elderly is muscle wastage and the resulting loss of strength, a condition known as sarcopenia. At about 55 years old, people begin to lose muscle mass, this loss continues into old age, at which point it becomes critical.

22 Jun 2016

Scientists discover how immune system molecule hijacks brain circuit to reduce appetite during illness

Loss of appetite during illness is a common and potentially debilitating phenomenon--in cancer patients, especially, it can even shorten lifespan.

5 May 2016

Mouse-based study shows exercise decreases cancer incidence, slows tumor growth

When you're pounding along an icy pavement or sweating through a gym workout, you try to remind yourself of the many health benefits of exercise. Between gasps, you can say that a healthy, fit lifestyle helps prevents obesity, a worldwide problem of increasing magnitude that has been linked to cardiovascular disease and diabetes.

11 Apr 2016

Helsinn, Mundipharma sign distribution, license and supply agreements for anamorelin

Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, today announce that they have entered into distribution, license and supply agreements with Mundipharma and its network of independent associated companies granting exclusive rights to anamorelin in Norway, Finland, Sweden, Denmark and Iceland.

16 Feb 2016

UofL researchers discover mechanism involved in skeletal muscle repair

Researchers at the University of Louisville have discovered a mechanism involved in skeletal muscle repair that may enable clinicians to boost the effectiveness of adult stem cell therapies for diseases such as muscular dystrophy.

1 Dec 2015

Helsinn one step closer to bringing anamorelin HCI to market for treatment of anorexia, cachexia in NSCLC patients

Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, today announced that the European Medicines Agency accepted for review, the marketing authorization application (MAA) for anamorelin HCI, a novel, orally active selective ghrelin receptor agonist under development for the treatment of anorexia, cachexia, or unintended weight loss in non-small cell lung cancer (NSCLC) patients.

30 Nov 2015

Experimental drug may stop life-threatening muscle wasting associated with advanced cancers

New data describes how an experimental drug can stop life-threatening muscle wasting (cachexia) associated with advanced cancers and restore muscle health. The experimental agent, known as AR-42 while in testing, was developed and tested in preclinical studies at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

25 Nov 2015

Researchers discover new gene that could be a potential therapeutic target for muscle wasting

It is estimated that half of all cancer patients suffer from a muscle wasting syndrome called cachexia. Cancer cachexia impairs quality of life and response to therapy, which increases morbidity and mortality of cancer patients. Currently, there is no approved treatment for muscle wasting but a new study from the Research Institute of the McGill University Health Centre and University of Alberta could be a game changer for patients, improving both quality of life and longevity.

15 Sep 2015

Helsinn, BIAL sign exclusive distribution and licence agreement for Anamorelin

Helsinn, the Swiss Group focused on building quality cancer care, and BIAL - Portela & Ca. S.A., one of the largest Iberian pharmaceutical companies, today announce that they have entered into an agreement for the exclusive distribution and licence rights to Anamorelin in Spain, Portugal, Angola and Mozambique.

8 Sep 2015

Scientists decipher new molecular signaling path that prompts protein degradation in muscle

Patients in advanced states of myocardial insufficiency generally lose their muscle mass and muscle strength. Indeed a fact that until now has negatively impacted the clinical course of the disease and that has resulted in poor prognoses for patients. Such pathological muscle loss impacts the skeletal muscles in particular.

11 Aug 2015

Gastrostomy methods equivalent in amyotrophic lateral sclerosis

The ProGas study results show that three methods of gastrostomy are equally good in terms of complications and survival in patients with amyotrophic lateral sclerosis.

4 Aug 2015

Gastrostomy methods equivalent in amyotrophic lateral sclerosis

The ProGas study results show that three methods of gastrostomy are equally good in terms of complications and survival in patients with amyotrophic lateral sclerosis.

4 Jun 2015

Moderate exercise on a regular basis may improve cancer treatments

Kansas State University kinesiology research offers encouraging information for cancer patients: A brisk walk or a slow jog on a regular basis may be the key to improved cancer treatments.

5 May 2015

Helsinn, Mundipharma sign distribution and license agreement for anamorelin

Helsinn, a Swiss Group focused on building quality cancer care, and Mundipharma, today announce that they have entered into a distribution and license agreement for the exclusive rights to anamorelin in China, Hong Kong and Macao.

26 Mar 2015

Anamorelin drug safe and well tolerated in advanced non-small cell lung cancer, Phase III trial reveals

A new drug, anamorelin, improves appetite and body mass in patients with advanced lung cancer who are suffering cancer anorexia and cachexia, according to phase III data presented at the ESMO 2014 Congress in Madrid, Spain.

29 Sep 2014

Scientists discover sign of early development of pancreatic cancer

Scientists at Dana-Farber Cancer Institute, the Massachusetts Institute of Technology, and other institutions have discovered a sign of the early development of pancreatic cancer - an upsurge in certain amino acids that occurs before the disease is diagnosed and symptoms appear.

29 Sep 2014

Helsinn to present Phase III trial data of anamorelin at ESMO Congress

Helsinn Group, a company focused on building quality cancer care, today announces that Phase III data from the largest trial program of its kind to date in anamorelin, a novel, once-daily ghrelin receptor agonist in development for cancer-anorexia-cachexia (CACS) in non-small cell lung cancer will be presented at the 38th European Society for Medical Oncology Congress in Madrid, Spain, in 2014.

25 Sep 2014

Cachexia News and Research

Further Reading

Mitofusin 2 protein could serve as therapeutic target to ameliorate sarcopenia in older adults

Scientists discover how immune system molecule hijacks brain circuit to reduce appetite during illness

Mouse-based study shows exercise decreases cancer incidence, slows tumor growth

Helsinn, Mundipharma sign distribution, license and supply agreements for anamorelin

UofL researchers discover mechanism involved in skeletal muscle repair

Helsinn one step closer to bringing anamorelin HCI to market for treatment of anorexia, cachexia in NSCLC patients

Experimental drug may stop life-threatening muscle wasting associated with advanced cancers

Researchers discover new gene that could be a potential therapeutic target for muscle wasting

Helsinn, BIAL sign exclusive distribution and licence agreement for Anamorelin

Scientists decipher new molecular signaling path that prompts protein degradation in muscle

Gastrostomy methods equivalent in amyotrophic lateral sclerosis

Gastrostomy methods equivalent in amyotrophic lateral sclerosis

Moderate exercise on a regular basis may improve cancer treatments

Helsinn, Mundipharma sign distribution and license agreement for anamorelin

Anamorelin drug safe and well tolerated in advanced non-small cell lung cancer, Phase III trial reveals

Scientists discover sign of early development of pancreatic cancer

Helsinn to present Phase III trial data of anamorelin at ESMO Congress

XBiotech reports interim results from Phase III study for anti-cancer agent Xilonix

Study pinpoints molecular cause of cachexia, hints at a potential treatment

Helsinn Group grants GEN Ilaç anamorelin rights for Turkey

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News